Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$102.80 USD

102.80
384,755

-2.21 (-2.10%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $102.78 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Ligand Pharmaceuticals Incorporated [LGND]

Reports for Purchase

Showing records 121 - 140 ( 720 total )

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 121

06/25/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 122

06/16/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 123

05/27/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 124

05/05/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 125

05/04/2021

Company Report

Pages: 6

1Q21 Results; OmniAb and Pelican Continue to Step Up Efforts

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 126

05/04/2021

Company Report

Pages: 7

1Q21 Recap - Noisy, but on Track

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 127

04/26/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 128

04/06/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 129

03/19/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 130

02/17/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 131

02/09/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 132

02/04/2021

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 133

02/04/2021

Company Report

Pages: 6

2020 Results; Fundamentals Have Never Been Better; Target Increased to $310

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 134

02/04/2021

Company Report

Pages: 9

4Q20 Recap - Next Product Wave Coming

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 135

02/02/2021

Company Report

Pages: 6

Groundhog Day of Positive Partner News

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 136

02/01/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 137

01/25/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 138

01/15/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 139

01/14/2021

Company Report

Pages: 7

Sparsentan Getting Closer to Providing Solid Royalty Stream; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 140

01/08/2021

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party
// eof